SEP achieves successful exit from Cmed

Date Published

Scottish Equity Partners (SEP) portfolio company Cmed Group has been acquired by the French Aixial Group, a leader in contact research organisation (CRO) services and part of Alten, the global engineering and technology consultancy business.

CMED, which is based in Horsham and has offices across the USA and Europe, consists of a global technology-led full services CRO and an e-clinical software technology business. The CRO specialises in complex disease areas, particularly oncology, immuno-oncology, cell therapy and other specialty therapeutics areas along with a strong data management and statistics heritage. Its technology division has also developed encapsia® an advanced, enterprise, cloud based clinical data system which delivers a complete solution to gather and manage multiple live clinical data sources and apply real-time data management, sophisticated visualizations, analytics and AI.

Aixial has over 1,000 employees across the United States and Europe and the acquisition will enable Cmed to build out its capabilities and expand its global presence to better serve its customers.

Commenting on the synergies between the two organisations David Connelly CEO of Cmed said: “When seeking a strategic step forward, we were fortunate to have many options. The choice of Aixial, with Alten behind us, expands our global reach and service offering to our valued clients. We are thrilled to join the Group and are excited about the future.”

Sign up to SEP news